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Sir, azole resistance in Aspergillus fumigatus is a global and evolving public health threat, which 
translates into treatment failure in different regions and patient groups worldwide [1] . The 
increasing trend of azole resistance in A. fumigatus, therefore, exemplifies the importance to 
explore alternative treatment strategies. 
The antimalarial drug chloroquine, an acidotropic agent that passively diffuses into acidic 
organelles, has shown to have a direct antifungal activity against Histoplasma capsulatum and 
Cryptococcus neoformans [2]. Moreover, synergistic interaction of chloroquine in combination 
with various antifungals has been reported on both azole-susceptible and azole-resistant 
Candida albicans isolates [3].  
Here, we investigated whether chloroquine potentiates the antifungal activity in combination 
with polyene and azole antifungals against both azole-susceptible and azole-resistant A. 
fumigatus isolates. 
A collection of thirty-one clinical A. fumigatus isolates, harboring various substitutions in the 
cyp-51A gene, was used in this study, including: single point mutations (M220I, M220K, M220I, 
G138C, G54W, A9T and F219I) and tandem repeat mutations (TR34/L98H and 
TR46/Y121F/T289A). Voriconazole-susceptible clinical isolates without mutations in the cyp-51A 
gene were used as wild-type controls (Table 1).  
Molecular identification, genotyping, antifungal susceptibility testing and drug interaction 
studies were performed, as described previously [4]. The final concentrations of the antifungal 
agents ranged from 0.016 to 16 mg/L for voriconazole and amphotericin B, from 0.06 to 64 
mg/L for caspofungin and the chloroquine diphosphate salt (Sigma-Aldrich, St. Louis, MO, USA; 
molecular weight, 515.9) concentrations ranged from 16 to 1024 mg/L.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4 
 
The in vitro interaction between chloroquine and voriconazole or amphotericin B or 
caspofungin was determined using a checkerboard microdilution method with 
spectrophotometric analysis and a viability-based XTT assay. In order to assess the nature of in 
vitro interactions between two drugs, the data obtained as described above were analyzed 
using fractional inhibitory concentration (FIC) index based on non-parametric Loewe additivity 
model, as described previously [4].  
The MIC and MEC characteristics of the 31 clinical A. fumigatus isolates are shown in Table 1. 
The mean MICs of voriconazole were 0.45 (0.25 to 0.5) mg/L for the voriconazole-susceptible 
isolates, whereas higher MICs were observed for isolates harboring mutations in the cyp-51A 
gene (mean MICs 6.17 mg/L, ranging 0.25 to >16 mg/L). 
Amphotericin B and caspofungin showed similar MIC and MEC values for the voriconazole-
susceptible and -resistant isolates with the MICs ranging from 0.25 to 1 mg/L and MECs from 
0.062 to 0.5 mg/L, respectively. The MICs of chloroquine against all isolates were > 1024 mg/L. 
No obvious interactions were found in vitro for all the combinations of chloroquine and 
voriconazole, and amphotericin B or caspofungin tested (Table 1). 
Our study showed that chloroquine had no growth-inhibitory antifungal activities against 
clinical A. fumigatus isolates, either voriconazole-susceptible or -resistant isolates. In addition, 
chloroquine in combination with different classes of antifungal agents, did not show any in vitro 
synergistic antifungal activity against A. fumigatus.   
The therapeutic actions of chloroquine and its interaction with antifungals have been 
investigated in a Saccharomyces cerevisiae yeast model and several pathogenic fungi, such as; 
H. capsulatum, C. neoformans, Candida spp. and A. fumigatus [3] . The mode of action against 
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Histoplasma and Candida spp. is thought to involve alkalinization of the host environment of 
the fungi through iron deprivation, increasing pH and inhibiting the thiamine transport The iron 
deprivation enhances the passive diffusion of drugs and causes down regulation of ERG11, 
which results in potentiated drug susceptibility. We previously showed that chloroquine exerts 
a direct pH-dependent antifungal effect on A. fumigatus and significantly increases the 
antifungal activity of polymorphonuclear cells [5]. 
Islahudin et al. reported that combination of chloroquine with caspofungin exhibited synergistic 
activity against C. albicans, C. glabrata, and S. cerevisiae in vitro [2]. By using a genome-wide 
yeast deletion strain collection of S. cerevisiae, it was shown that chloroquine hypersensitivity 
was associated with the presence of deletion mutants in the cell wall integrity pathway. The 
MIC of caspofungin against C. albicans was decreased 2-fold by 250 μM chloroquine and up to 
8-fold at higher chloroquine concentrations. Similar effects were seen in C. glabrata and A. 
fumigatus. Of note, only one strain, the AF 293 was used, which is less virulent than all of the 
clinical isolates tested by us. More recently, Li et al. showed that chloroquine had poor 
antifungal activity against Candida spp., however synergistic interaction between chloroquine 
and fluconazole against fluconazole-resistant C. albicans, C. krusei, and C. tropicalis isolates was 
reported [3].  
Our findings stand in contrast to the results as shown for Candida spp and suggest that 
postulated mechanism of fungicidal synergism between cell membrane- and cell wall-active 
agents and chloroquine, are different between yeasts and molds. Iron deprivation thought to 
cause a decrease in the level of sterols may lead to less increase in membrane fluidity in molds 
and therefore less enhancement of passive diffusion of drugs into the fungal cell. A second 
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mode of action of chloroquine via iron deprivation is thought to be the downregulation of 
ERG11 in Candida spp. leading to increased susceptibility to fluconazole. While A. fumigatus is 
inherently resistant to fluconazole, the regulation of the ERG11 genes involved in the 
susceptibility to the mold-active azoles clearly differs [5].  
In conclusion, although our study showed no in vitro activity of chloroquine alone or in 
combination with voriconazole or amphotericin B or caspofungin against A. fumigatus, our 
previous observation that chloroquine increases the antifungal activity of neutrophils may 
however suggest that chloroquine exerts different effects in vivo. Therefore, investigating the 
therapeutic efficacy of chloroquine in an experimental murine model of invasive aspergillosis is 
needed to assess its value in the treatment of infections caused by A. fumigatus.  
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ID number 
 
Origin 
 
Cyp-51A 
substitution 
MIC/MEC (mg/L) 
VRC AmB CAS CQ 
Single Combined Single Combined Single Combined Single Combined 
AZN 8196 Proven IA None 0.25 0.25 0.25 0.125 0.25 0.25 > 1024 > 1024 
V 52-76 Proven IA None 0.5 0.25 - - - - > 1024 > 1024 
V 28-29 Proven IA None 0.5 0.25 - - - - > 1024 > 1024 
V 67-38 chronic PA None 0.5 0.5 - - - - > 1024 > 1024 
V 12-74 Proven IA None 0.5 0.5 - - - - > 1024 > 1024 
V 54-09 Proven IA None 0.5 0.5 - - - - > 1024 > 1024 
           
V 67-37 chronic PA None 2 2 0.25 0.25 0.25 0.25 > 1024 > 1024 
V 67-35 Chronic PA None 4 4 - - - - > 1024 > 1024 
V 67-36 chronic  PA None 4 2 - - - - > 1024 > 1024 
           
V 13-09 Probable IA M220V 2 2 1 0.5 0.25 0.25 > 1024 > 1024 
V 59-27 Allergic PA M220K 2 1 - - - - > 1024 > 1024 
V 28-77 Aspergilloma M220I 0.5 0.5 - - - - > 1024 > 1024 
           
V 59-72 Aspergilloma G138C 2 1 0.25 0.25 0.25 0.25 > 1024 > 1024 
V 79-25 Proven IA G54W 0.25 0.25 - - - - > 1024 > 1024 
V 59-73 Proven IA G54W 0.25 0.125 - - - - > 1024 > 1024 
           
V 44-58 Proven IA TR34/L98H 4 4 - - - - > 1024 > 1024 
V 52-35 Proven IA TR34/L98H 4 4 0.25 0.25 0.25 0.25 > 1024 > 1024 
V 61-76 Proven IA TR34/L98H 4 4 - - - - > 1024 > 1024 
V 64-51 Proven IA TR34/L98H 8 8 - - - - > 1024 > 1024 
V 64-72 Proven IA TR34/L98H 8 8 - - - - > 1024 > 1024 
V 79-79 Proven IA TR34/L98H 8 8 - - - - > 1024 > 1024 
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V 45-07 Proven IA TR34/L98H 8 8 - - - - > 1024 > 1024 
V 77-40 Proven IA TR34/L98H 8 8 - - - - > 1024 > 1024 
V 80-01 Proven IA TR34/L98H 16 16 - - - - > 1024 > 1024 
           
V 94-10 Proven IA TR46/Y121F/T289A >16 > 16 0.25 0.25 0.062 0.062 > 1024 > 1024 
V 99-47 Proven IA TR46/Y121F/T289A >16 >16 - - - - > 1024 > 1024 
V 107-65 Proven IA TR46/Y121F/T289A >16 >16 - - - - > 1024 > 1024 
V 104-35 Proven IA TR46/Y121F/T289A >16 >16 - - - - > 1024 > 1024 
           
V 74-61 Proven IA A9T 1 1 - - - - > 1024 > 1024 
V 76-03 Proven IA A9T, F219I 0.25 0.25 0.25 0.25 0.125 0.125 > 1024 > 1024 
V 79-063 Proven IA A9T, F219I 4 4 - - - - > 1024 > 1024 
 
 
Table 1: The results of susceptibility tests for voriconazole, amphotericin B and caspofungin alone or in combination with 
chloroquine against voriconazole-susceptible and voriconazole-resistant- (substitutions in the cyp-51A gene, including single point 
[M220V, M220K, M220I, G54W, G138C, G54W, A9T, F219I] and tandem repeat [34-bp tandem repeat in the promoter region of the 
cyp51A gene in combination with substitutions at codon L98 and 46-bp tandem repeat in the promoter region of the cyp-51A gene 
in combination with mutation at codons Y121 and T289] mutations) clinical Aspergillus fumigatus isolates using a checkerboard 
microdilution method with spectrophotometric analysis. 
VRC: Voriconazole, AmB: Amphotericin B, CAS: Caspofungin, CQ: Chloroquine. 
